Accelerated bookbuild offering - Joint Global Coordinator & Joint Bookrunner MDxHealth

Kempen is pleased to announce the successful EUR 36 million capital increase via an accelerated bookbuild offering by MDxHealth

Transaction highlights

  • The capital increase represented 20% of MDxHealth’s pre-deal outstanding share capital, at an issue price of EUR 3.60 per share, resulting in gross proceeds of EUR 36 million, the largest capital raise in the company’s history.
  • Kempen has been instrumental in obtaining the support of the company’s key shareholders Biovest and Valiance who indicated their intention to participate ahead of launch of the transaction
  • The pre-launch market sounding exercise indicated firm support to the transaction, allowing the accelerated book-building process to generate strong demand from US and European Life Science specialist and generalist investors, resulting in a multiple times oversubscribed order book
  • Kempen was involved in c.90% of the final allocations to investors, thereby strongly delivering upon the company’s goal to diversify its shareholder base
  • Over the years, Kempen has developed a unique expertise in the area of innovative diagnostics products with active coverage of most leading European diagnostics companies. Our lead role in MDxHealth’s current transaction builds on our successful involvement in raising over EUR 260 million of equity for diagnostics companies in recent years. 
  • Transaction proceeds are envisaged to be used to grow the business by executing its sales strategy, launching InformMDx and further developing its pipeline

Company description

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalise the diagnosis and treatment of urological cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.

Contact

Jan De Kerpel

Transactions

No results were found